Journal Article10.3892/ijo.2024.5669
mRNA vaccine development and applications: A special focus on tumors (Review)
Bangjie Chen,Yipin Yang,Xinyi Wang,Wen-Zhi Yang,You Lu,Daoyue Wang,Enba Zhuo,Yanchao Tang,Junhong Su,Guozheng Tang,Song Shao,Kangsheng Gu +11 more
1
TL;DR: The development of mRNA vaccines, their mechanisms of action, factors influencing their function and the current clinical applications of the vaccine are discussed, with a focus on the application of mRNA vaccines in cancer.
read more
Abstract: Cancer is characterized by unlimited proliferation and metastasis, and traditional therapeutic strategies usually result in the acquisition of drug resistance, thus highlighting the need for more personalized treatment. mRNA vaccines transfer the gene sequences of exogenous target antigens into human cells through transcription and translation to stimulate the body to produce specific immune responses against the encoded proteins, so as to enable the body to obtain immune protection against said antigens; this approach may be adopted for personalized cancer therapy. Since the recent coronavirus pandemic, the development of mRNA vaccines has seen substantial progress and widespread adoption. In the present review, the development of mRNA vaccines, their mechanisms of action, factors influencing their function and the current clinical applications of the vaccine are discussed. A focus is placed on the application of mRNA vaccines in cancer, with the aim of highlighting unique advances and the remaining challenges of this novel and promising therapeutic approach.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
References
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
Brenda De Keersmaecker,Sofie Claerhout,Javier Carrasco,Isabelle Bar,Jurgen Corthals,Sofie Wilgenhof,Bart Neyns,Kris Thielemans +7 more
TL;DR: The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.
118
Clinical and immunological effects of mRNA vaccines in malignant diseases.
TL;DR: In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and highly efficient class of drugs and have been shown to induce polyclonal CD4+ and CD8+ mediated antigen-specific T cell responses as well as the production of protective antibodies with the ability to eliminate transformed or infected cells as mentioned in this paper.
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
TL;DR: This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.
106
Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
Kirtika H. Asrani,Jeremiah D. Farelli,Mary R Stahley,Rebecca L Miller,Christopher J. Cheng,Romesh R. Subramanian,Jeffrey M Brown +6 more
TL;DR: The 5′ UTR appears to be the key driver in protein expression for exogenously delivered mRNA, and from the testing of the combinatorial library, the 5′UTR for complement factor 3 (C3) and cytochrome p4502E1 (CYP2E2) showed the largest and most consistent increase inprotein expression relative to a reference UTR.
105
Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles.
TL;DR: This is the first study to show the therapeutic potential of introducing exogenous mRNA for the treatment of neurological disorders, and establishes a novel carrier based on the self-assembly of polyethylene glycol-polyamino acid block copolymer, i.e. polyplex nanomicelles to provide a novel strategy of mRNA-based therapy.
104